NR3C1 and posterior cortical atrophy: Further, establishing the contribution of GR signaling to PCa therapy cross-resistance is highly relevant clinically given that both ARSI and taxane chemotherapy are administered to patients with mCRPC concomitantly with glucocorticoids (e.g., dexamethasone, prednisone, or prednisolone) to ameliorate the side effects of the drugs and make the chemotherapeutic regimens more tolerable [64,65].